CompletedNot applicableNCT01302626
Official study title

Radiomics: a Study of Outcome in Lung Cancer

Study summary

Aim of the study: The main aim is to collect data of patients with lung cancer, and to perform different analyses on this data. The data contains information on patient and tumor characteristics, imaging, and treatment characteristics. With this data it is possible to improve and validate the predictive model for survival and long term toxicity in lung cancer by multicentric prospective data collection. The long term aim, beyond this specific study, is to build a Decision Support System based on the predictive models validated in this study. Hypothesis: The general hypothesis is that we get a better prediction in terms of AUC (area under the curve) of survival and long term toxicity when we combine multifactorial variables. These variables consist of information from clinical data, imaging data, data related to treatment type and treatment quality.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedNot specified

The study team can explain what participation involves.

Who it may be forLung Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Mar 22, 2017 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?3 U.S. locations

Locations may change over time.

Who runs it?Maastricht Radiation Oncology

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Maastricht Radiation Oncology
Interventions being studied
Not specified
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Histological or cytological proven lung cancer (small cell or non-small cell);
  • 18 years or older;
  • Informed consent according to national rules (US: written informed consent, NL: no objection rule)

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • H. Lee Moffitt Cancer Center and Research InstituteTampa, Florida
  • Gemelli Hospital Roma / Universita Cattolica del Sacre Cuore RomeRome
  • Maastro clinic, University Hospital of MaastrichtMaastricht, Limburg

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 22, 2017. Always confirm current availability with the study team.

View original record ↗